Related Experiment Video

Updated: Feb 23, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Interferon treatment of HCV positive cirrhotic patients

R Idilman1, A Colantoni, N De Maria

  • 1Department of Medicine, University of Kentucky School of Medicine, Lexington 40536, USA.

Hepato-Gastroenterology
|June 25, 1998
PubMed

Insights

Interferon therapy can effectively treat chronic hepatitis C, even in patients with cirrhosis. This treatment helps reduce liver inflammation and clear the virus, challenging previous assumptions about its safety and efficacy in advanced liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Chronic hepatitis C (HCV) affects 3.5 million in the US, causing significant mortality from liver complications.
  • Effective screening has reduced post-transfusion HCV, but it remains a clinical challenge.
  • Interferon (IFN) therapy is a primary treatment for advanced hepatitis C, aiming to reduce inflammation and eliminate the virus.

Purpose of the Study:

  • To challenge the assumption that cirrhotic patients with chronic hepatitis C do not respond to IFN therapy.
  • To review the safety and efficacy of IFN treatment in cirrhotic patients with chronic hepatitis C.
  • To evaluate the potential of IFN therapy in preventing the progression of liver disease.

Main Methods:

  • Review of existing studies on interferon therapy for chronic hepatitis C.
  • Analysis of treatment response rates in cirrhotic versus non-cirrhotic patients.
  • Assessment of adverse events, specifically hepatic decompensation, in treated cirrhotic patients.

Main Results:

  • Cirrhotic patients with chronic hepatitis C demonstrate a response to IFN therapy, albeit at approximately half the rate of non-cirrhotic patients.
  • No cases of hepatic decompensation were reported as a consequence of IFN treatment in cirrhotic individuals.
  • IFN therapy has been shown to induce remission of hepatic inflammation and viral clearance in treated patients.

Conclusions:

  • The assumption that cirrhotic individuals with chronic hepatitis C do not benefit from or are endangered by IFN therapy is false.
  • Interferon therapy is a viable and safe treatment option for cirrhotic patients with chronic hepatitis C.
  • IFN treatment can help manage liver inflammation and viral load, potentially preventing disease progression.

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.5K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
273
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
411
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K